Supriya Lifescience Files SEBI Compliance Certificate for Q4FY26
Supriya Lifescience Limited submitted a compliance certificate for the quarter ended March 31, 2026. The certificate, issued by MUFG Intime India, confirms adherence to SEBI (Depositories and Participants) Regulations, 2018 regarding dematerialization and listing of securities.
This is a standard regulatory filing for the quarter-end and does not involve any significant corporate actions or financial results that would materially impact the company's operations or stock price.
The announcement is a routine compliance filing and does not contain any new financial information or strategic updates that would impact the company's sentiment.
Supriya Lifescience Limited has submitted a certificate confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This certificate pertains to the quarter ended March 31, 2026.
The certificate was issued by MUFG Intime India Private Limited, the company's Registrar and Share Transfer Agent, on April 3, 2026. It confirms that all securities received for dematerialization during the specified quarter were processed, confirmed (accepted/rejected), and listed on the stock exchanges where the company's securities are already traded. Furthermore, the registrar confirmed that the received security certificates were mutilated and cancelled after verification, and the depositories were substituted as the registered owner within the prescribed timelines.
The company has requested that this information be taken on record.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.